ArticleOncotarget2017
Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.International journal of molecular sciences · 2025Review
- Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.Acta pharmaceutica Sinica. B · 2024Review
- Involvement of platelet signaling pathways in colorectal cancer and new therapeutic targets.American journal of cancer research · 2024Review
- Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.Journal of biomedical science · 2023Review
- Cell-Based Drug Delivery Systems with Innate Homing Capability as a Novel Nanocarrier Platform.International journal of nanomedicine · 2023Review
- Synthetic cells in biomedical applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Bacteria and cells as alternative nano-carriers for biomedical applications.Expert opinion on drug delivery · 2022Review
- Combination of Nanomaterials in Cell-Based Drug Delivery Systems for Cancer Treatment.Pharmaceutics · 2021Review
- Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.Scientific reports · 2021Article
- Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction.Translational oncology · 2021Review
- Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues.Frontiers in oncology · 2021Review
- Horizontal MicroRNA Transfer by Platelets - Evidence and Implications.Frontiers in physiology · 2021Review
- Cell-mediated targeting drugs delivery systems.Drug delivery · 2020Review
- Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment.Acta pharmaceutica Sinica. B · 2020Review
- Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells.Nanoscale advances · 2020Article
- Adipocyte-Based Cell Therapy in Oncology: The Role of Cancer-Associated Adipocytes and Their Reinterpretation as Delivery Platforms.Pharmaceutics · 2020Review
- Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.International journal of nanomedicine · 2020Article
- Cells and cell derivatives as drug carriers for targeted delivery.Medicine in drug discovery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell lymphoma accounts for approximately 85% of all adult non-Hodgkin's lymphoma cases. Doxorubicin (DOX) is an indispensable drug for the treatment of non-Hodgkin's lymphoma. However, DOX causes severe cardiotoxicity, which limits its use in conventional treatment strategies. In this study, we developed a novel drug delivery system for lymphoma treatment: DOX-loaded platelets that were conjugated with anti-CD22 monoclonal antibodies (mAbs) (DOX-platelet-CD22). Platelets are bio- and immune-compatible drug carriers that can prolong the circulation time of drugs. Anti-CD22 mAb-labeled platelets can precisely deliver DOX to tumor cells. Our
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.